In a comprehensive Genomic Press Interview, Dr. Kerry Ressler, Chief Scientific Officer at McLean Hospital and Professor of Psychiatry at Harvard Medical School, unveils groundbreaking advances in understanding the neurobiological basis of post-traumatic stress disorder (PTSD) and related anxiety conditions.
Promising Findings for Nipocalimab in Myasthenia Gravis
Fixed-dose treatment with nipocalimab, an investigational neonatal Fc receptor blocker, lessened disease severity in generalized myasthenia gravis, according to pivotal phase III data presented at
October 30, 2024